AAAAAA
Results:
1-17
|
Results: 17
Authors:
Smith, TJ
Hillner, BE
Citation: Tj. Smith et Be. Hillner, Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways, J CL ONCOL, 19(11), 2001, pp. 2886-2897
Authors:
Hillner, BE
Citation: Be. Hillner, Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease, SEMIN ONCOL, 28(4), 2001, pp. 64-68
Authors:
Hillner, BE
Kirkwood, JM
Agarwala, SS
Citation: Be. Hillner et al., Burden of illness associated with metastatic melanoma - An audit of 100 consecutive referral center cases, CANCER, 91(9), 2001, pp. 1814-1821
Authors:
Hillner, BE
Radice, D
Citation: Be. Hillner et D. Radice, Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma, CANCER, 91(3), 2001, pp. 484-489
Authors:
Hillner, BE
Roberts, JD
Citation: Be. Hillner et Jd. Roberts, Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer, J NAT CANC, 92(21), 2000, pp. 1704-1706
Authors:
Hillner, BE
Citation: Be. Hillner, The role of bisphosphonates in metastatic breast cancer, SEM RAD ONC, 10(3), 2000, pp. 250-253
Authors:
Smith, TJ
Hillner, BE
Citation: Tj. Smith et Be. Hillner, Is tamoxifen cost-effective for prevention of breast cancer? Reply, J CL ONCOL, 18(8), 2000, pp. 1807-1807
Authors:
Hillner, BE
Agarwala, S
Middleton, MR
Citation: Be. Hillner et al., Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma, J CL ONCOL, 18(7), 2000, pp. 1474-1480
Authors:
Hillner, BE
Ingle, JN
Berenson, JR
Janjan, NA
Albain, KS
Lipton, A
Yee, G
Biermann, JS
Chlebowski, RT
Pfister, DG
Citation: Be. Hillner et al., American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer, J CL ONCOL, 18(6), 2000, pp. 1378-1391
Authors:
Smith, TJ
Hillner, BE
Citation: Tj. Smith et Be. Hillner, Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women, J CL ONCOL, 18(2), 2000, pp. 284-286
Authors:
Hayman, JA
Hillner, BE
Harris, JR
Pierce, LJ
Weeks, JC
Citation: Ja. Hayman et al., Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast cancer, J CL ONCOL, 18(2), 2000, pp. 287-295
Authors:
Hillner, BE
Citation: Be. Hillner, Survival gain in cost-effectiveness studies - In reply, J CL ONCOL, 18(18), 2000, pp. 3318-3318
Authors:
Hillner, BE
Smith, TJ
Desch, CE
Citation: Be. Hillner et al., Hospital and physician volume or specialization and outcomes in cancer treatment: Importance in quality of cancer care, J CL ONCOL, 18(11), 2000, pp. 2327-2340
Authors:
Hillner, BE
Weeks, JC
Desch, CE
Smith, TJ
Citation: Be. Hillner et al., Pamidronate in prevention of bone complications in metastatic breast cancer: A cost-effectiveness analysis, J CL ONCOL, 18(1), 2000, pp. 72-79
Authors:
Hayman, JA
Hillner, BE
Citation: Ja. Hayman et Be. Hillner, Is the use of radiation therapy after mastectomy cost-effective?, SEM RAD ONC, 9(3), 1999, pp. 287-291
Authors:
Desch, CE
Penberthy, LT
Hillner, BE
McDonald, MK
Smith, TJ
Pozez, AL
Retchin, SM
Citation: Ce. Desch et al., A sociodemographic and economic comparison of breast reconstruction, mastectomy, and conservative surgery, SURGERY, 125(4), 1999, pp. 441-447
Authors:
Hillner, BE
Citation: Be. Hillner, Review of cost-effectiveness assessments of chemotherapy in adjuvant and advanced breast cancer, ANTI-CANC D, 9(10), 1998, pp. 843-847
Risultati:
1-17
|